Vident Advisory’s AbbVie ABBV Stock Holding History

Vident Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.4M	Buy	176,635 +25,365	+17%	+$5.63M	0.33%	58
2025 Q4	$34.6M	Buy	151,270 +2,499	+2%	+$569K	0.31%	68
2025 Q3	$34.4M	Buy	148,771 +5,909	+4%	+$1.2M	0.33%	65
2025 Q2	$26.5M	Buy	142,862 +8,859	+7%	+$1.65M	0.3%	79
2025 Q1	$28.1M	Buy	134,003 +41,386	+45%	+$8.05M	0.41%	52
2024 Q4	$16.5M	Buy	92,617 +15,110	+19%	+$2.78M	0.29%	74
2024 Q3	$15.3M	Sell	77,507 -5,242	-6%	-$978K	0.39%	52
2024 Q2	$14.2M	Sell	82,749 -215,848	-72%	-$35.8M	0.39%	53
2024 Q1	$54.4M	Buy	298,597 +54,803	+22%	+$9.44M	1.13%	6
2023 Q4	$37.8M	Sell	243,794 -1,062	-0.4%	-$155K	0.95%	9
2023 Q3	$36.5M	Buy	+244,856	New	+$35.9M	1.13%	8

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vident Advisory's ABBV Position: Q1 2026 in Review

Vident Advisory increased its AbbVie (ABBV) stake by 17% in Q1 2026, buying an estimated $5.63M and bringing the position to 176,635 shares worth $38.4M. The position accounts for 0.33% of the portfolio, ranked #58.

Vident Advisory first reported a position in ABBV in Q3 2023 and has held it in 11 quarters since. The position peaked at $54.4M in Q1 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Vident Advisory held 176,635 shares of AbbVie worth $38.4M as of Q1 2026.
Vident Advisory bought 25,365 AbbVie shares in Q1 2026, an estimated $5.63M.
AbbVie made up 0.33% of Vident Advisory's portfolio in Q1 2026, its #58 holding.
Vident Advisory first reported a position in AbbVie in Q3 2023 and has held it in 11 quarters since.
Vident Advisory's AbbVie position peaked at $54.4M in Q1 2024.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.